Ziqiang Chen

Merck & Co., Inc., Rahway, NJ, USA (United States)

ORCID: 0009-0001-6888-2084

Also affiliated with Suizhou Central Hospital, Fujian Academy of Agricultural Sciences, Changchun University of Chinese Medicine, Institute of Quality Standards and Testing Technology for Agro Products, Chengdu University of Traditional Chinese Medicine

EngineeringMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “167. Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease”.

167. Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease

Open Forum Infectious Diseases(2025)10.1093/ofid/ofae631.004

N/A

0DataRank · unranked

4 citations

Louis Bont, Paolo Manzoni, Flor M. Muñoz, Octavio Ramilo, Po‐Yen Chen +16 more